[1]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-WO2003/106416,2003,A2Locationinpatent:Page54
[2]CurrentPatentAssignee:KUMAR;GLAXOSMITHKLINEPLC-WO2005/105094,2005,A2Locationinpatent:Page/Pagecolumn41-42
[1]Patent:US2015/329526,2015,A1.Locationinpatent:Paragraph0040
[2]Patent:WO2007/64753,2007,A2.Locationinpatent:Page/Pagecolumn31-32
[3]Patent:WO2003/106416,2003,A2.Locationinpatent:Page52-53
[4]Patent:WO2006/20564,2006,A1.Locationinpatent:Page/Pagecolumn18-19
[5]Patent:US2008/293691,2008,A1.Locationinpatent:Page/Pagecolumn12-13
[6]Patent:WO2005/105094,2005,A2.Locationinpatent:Page/Pagecolumn40
[7]Patent:WO2007/143483,2007,A2.Locationinpatent:Page/Pagecolumn34-35
[8]Patent:WO2007/64753,2007,A2.Locationinpatent:Page/Pagecolumn32
[9]Patent:WO2003/106416,2003,A2.Locationinpatent:Page53-54
[10]Patent:WO2006/20564,2006,A1.Locationinpatent:Page/Pagecolumn19
[11]Patent:US2008/293691,2008,A1.Locationinpatent:Page/Pagecolumn13
[12]Patent:WO2005/105094,2005,A2.Locationinpatent:Page/Pagecolumn41
[13]Patent:WO2007/143483,2007,A2.Locationinpatent:Page/Pagecolumn35
[14]Patent:WO2011/69053,2011,A1.Locationinpatent:Page/Pagecolumn38-39
[15]Patent:WO2007/64753,2007,A2.Locationinpatent:Page/Pagecolumn33
[16]JournalofMedicinalChemistry,2008,vol.51,p.4632-4640
[17]Patent:WO2007/143483,2007,A2.Locationinpatent:Page/Pagecolumn36
[18]Patent:WO2007/64753,2007,A2.Locationinpatent:Page/Pagecolumn33
[19]Patent:WO2003/106416,2003,A2.Locationinpatent:Page54
[20]Patent:WO2006/20564,2006,A1.Locationinpatent:Page/Pagecolumn19
[21]Patent:US2008/293691,2008,A1.Locationinpatent:Page/Pagecolumn13
[22]Patent:WO2005/105094,2005,A2.Locationinpatent:Page/Pagecolumn41
[23]Patent:WO2007/143483,2007,A2.Locationinpatent:Page/Pagecolumn35-36
[24]Patent:WO2007/64753,2007,A2.Locationinpatent:Page/Pagecolumn32
[25]Patent:WO2003/106416,2003,A2.Locationinpatent:Page53
[26]Patent:WO2006/20564,2006,A1.Locationinpatent:Page/Pagecolumn19
[27]Patent:US2008/293691,2008,A1.Locationinpatent:Page/Pagecolumn13
[28]Patent:WO2005/105094,2005,A2.Locationinpatent:Page/Pagecolumn40-41
[29]Patent:WO2007/143483,2007,A2.Locationinpatent:Page/Pagecolumn35
[30]Pharmazie,2018,vol.73,p.494-497
[31]Patent:WO2007/64753,2007,A2.Locationinpatent:Page/Pagecolumn31
[32]Patent:WO2003/106416,2003,A2.Locationinpatent:Page52
[33]Patent:WO2006/20564,2006,A1.Locationinpatent:Page/Pagecolumn18
[34]LettersinOrganicChemistry,2012,vol.9,p.276-279
[35]Patent:WO2011/50159,2011,A1.Locationinpatent:Page/Pagecolumn25-26
[36]Patent:EP2311825,2015,B1.Locationinpatent:Paragraph0345;0346
[37]Patent:US2008/293691,2008,A1.Locationinpatent:Page/Pagecolumn12
[38]Patent:WO2005/105094,2005,A2.Locationinpatent:Page/Pagecolumn39
[39]Patent:WO2007/143483,2007,A2.Locationinpatent:Page/Pagecolumn34
[1]CurrentPatentAssignee:GLAXOSMITHKLINEPLC;NOVARTISAG;Novartis(w/oSandoz)-WO2007/64753,2007,A2Locationinpatent:Page/Pagecolumn34
[2]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-US2008/293691,2008,A1Locationinpatent:Page/Pagecolumn13
[3]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-WO2007/143483,2007,A2Locationinpatent:Page/Pagecolumn36-37
[1]Patent:WO2009/62658,2009,A1.Locationinpatent:Page/Pagecolumn36;1/10
Title: Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles.
Journal: Archives of toxicology 20180401
Title: Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.
Journal: Chemical research in toxicology 20170515
Title: Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20150601
Title: A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20131101
Title: Pazopanib, a new therapy for metastatic soft tissue sarcoma.
Journal: Expert opinion on pharmacotherapy 20130501
Title: Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20130501
Title: Pazopanib: in advanced soft tissue sarcoma.
Journal: Drugs 20121112
Title: An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
Journal: European journal of cancer (Oxford, England : 1990) 20121101
Title: Favorable course of pericardial angiosarcoma under paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging.
Journal: Circulation 20121030
Title: Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
Journal: International journal of pharmaceutics 20121015
Title: Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120915
Title: Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.
Journal: Pediatric blood & cancer 20120901
Title: A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway.
Journal: Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20120901
Title: Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
Journal: Retina (Philadelphia, Pa.) 20120901
Title: A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.
Journal: The Journal of clinical endocrinology and metabolism 20120901
Title: Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Journal: Expert opinion on drug safety 20120901
Title: Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120901
Title: [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Journal: Magyar onkologia 20120901
Title: Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.
Journal: Expert review of anticancer therapy 20120901
Title: Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases.
Journal: Chemical communications (Cambridge, England) 20120825
Title: Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.
Journal: British journal of cancer 20120807
Title: The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.
Journal: Investigational new drugs 20120801
Title: A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.
Journal: Investigational new drugs 20120801
Title: Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.
Journal: Molecular cancer therapeutics 20120801
Title: Concise drug review: pazopanib and axitinib.
Journal: The oncologist 20120801
Title: Biomarkers in personalised treatment of renal-cell carcinoma.
Journal: The Lancet. Oncology 20120801
Title: Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Journal: The Lancet. Oncology 20120801
Title: Antiangiogenic treatment in metastatic urothelial cancer.
Journal: The Lancet. Oncology 20120801
Title: Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
Journal: The Lancet. Oncology 20120801
Title: [Soft-tissue sarcoma: recent developments].
Journal: Deutsche medizinische Wochenschrift (1946) 20120801
Title: Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS).
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120715
Title: Targeted therapies: pazopanib for soft-tissue sarcoma: a PALETTE of data emerges.
Journal: Nature reviews. Clinical oncology 20120703
Title: Decade of molecular targeted therapy: abdominal manifestations of drug toxicities--what radiologists should know.
Journal: AJR. American journal of roentgenology 20120701
Title: Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report.
Journal: Targeted oncology 20120601
Title: Current treatment considerations in metastatic renal cell carcinoma.
Journal: Current treatment options in oncology 20120601
Title: Pazopanib in the treatment of soft tissue sarcoma.
Journal: Expert review of anticancer therapy 20120601
Title: Rapid analysis of whole blood by paper spray mass spectrometry for point-of-care therapeutic drug monitoring.
Journal: The Analyst 20120521
Title: Pazopanib and the treatment palette for soft-tissue sarcoma.
Journal: Lancet (London, England) 20120519
Title: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
Journal: Lancet (London, England) 20120519
Title: Novel molecular targeted therapies for refractory thyroid cancer.
Journal: Head & neck 20120501
Title: Targeted therapeutic strategies for the management of renal cell carcinoma.
Journal: Current opinion in oncology 20120501
Title: [First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell cancer (SWITCH-2 - AN 33/11)].
Journal: Der Urologe. Ausg. A 20120501
Title: Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Journal: Journal of cancer research and clinical oncology 20120401
Title: Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120310
Title: A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.
Journal: Prostate cancer and prostatic diseases 20120301
Title: Pazopanib for the treatment of metastatic renal cell carcinoma.
Journal: Clinical therapeutics 20120301
Title: [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Journal: Magyar onkologia 20120301
Title: Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group.
Journal: British journal of cancer 20120214
Title: Second-line treatment for renal cell cancer.
Journal: British journal of cancer 20120214
Title: Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.
Journal: European journal of cancer (Oxford, England : 1990) 20120201
Title: Pazopanib for the treatment of breast cancer.
Journal: Expert opinion on investigational drugs 20120201
Title: Nursing considerations for patients receiving pazopanib for renal cell carcinoma.
Journal: ONS connect 20120201
Title: Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Journal: Journal of the National Cancer Institute 20120118
Title: An update on targeted therapy in metastatic renal cell carcinoma.
Journal: Urologic oncology 20120101
Title: Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Journal: Journal of biochemistry 20120101
Title: Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
Journal: Oncology 20120101
Title: [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].
Journal: Revue medicale de Liege 20120101
Title: Reversible posterior leukoencephalopathy syndrome induced by pazopanib.
Journal: BMC cancer 20120101
Title: Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report.
Journal: Clinical genitourinary cancer 20111201
Title: Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
Journal: Future oncology (London, England) 20111201
Title: Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Journal: The Canadian journal of urology 20111201
Title: Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20111101
Title: Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage.
Journal: Microvascular research 20111101
Title: The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20111101
Title: Tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Journal: Drug and therapeutics bulletin 20111101
Title: [Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].
Journal: Bulletin du cancer 20111001
Title: Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.
Journal: Clinical journal of oncology nursing 20111001
Title: Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer.
Journal: Urology 20111001
Title: [Dermatologic side effects induced by new angiogenesis inhibitors].
Journal: Bulletin du cancer 20111001
Title: Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
Journal: European journal of pharmacology 20110901
Title: Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110901
Title: [Pharmacological sheet: pazopanib (Votrient), oral administration].
Journal: Journal de pharmacie de Belgique 20110901
Title: A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110815
Title: Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
Journal: Hematology/oncology clinics of North America 20110801
Title: Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines.
Journal: The Canadian journal of urology 20110801
Title: [Systemic treatment of renal cell carcinoma - recent update].
Journal: Wiener medizinische Wochenschrift (1946) 20110801
Title: Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells.
Journal: Urology 20110701
Title: [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Journal: Aktuelle Urologie 20110701
Title: Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110620
Title: Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma.
Journal: Journal of hepatology 20110601
Title: Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Journal: Clinical therapeutics 20110601
Title: Pazopanib for the treatment of renal cancer.
Journal: Expert opinion on pharmacotherapy 20110501
Title: [Novelties in the treatment for advanced renal-cell cancer].
Journal: Orvosi hetilap 20110424
Title: [Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or local advanced renal cell carcinoma after nephrectomy].
Journal: Der Urologe. Ausg. A 20110401
Title: [Treatment of metastatic renal cell carcinoma].
Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20110401
Title: Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Journal: Drugs 20110305
Title: Pazopanib: Clinical development of a potent anti-angiogenic drug.
Journal: Critical reviews in oncology/hematology 20110301
Title: NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma.
Journal: The Lancet. Oncology 20110301
Title: Pazopanib. Kidney cancer: many risks, but is there a benefit for patients?
Journal: Prescrire international 20110301
Title: Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: an example of pazopanib complication.
Journal: Clinics and research in hepatology and gastroenterology 20110201
Title: Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110101
Title: In pursuit of new anti-angiogenic therapies for cancer treatment.
Journal: Frontiers in bioscience (Landmark edition) 20110101
Title: Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.
Journal: BMC cancer 20110101
Title: Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors.
Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101
Title: The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models.
Journal: PloS one 20110101
Title: The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
Journal: BMC cancer 20110101
Title: Pazopanib in renal cell carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20101215
Title: Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20101201
Title: The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro.
Journal: Toxicology and applied pharmacology 20101201
Title: A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.
Journal: Molecular cancer therapeutics 20101201
Title: A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.
Journal: Clinical pharmacology and therapeutics 20101201
Title: Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.
Journal: The oncologist 20101201
Title: [Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].
Journal: Magyar onkologia 20101201
Title: An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
Journal: Clinical pharmacology and therapeutics 20101101
Title: Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules.
Journal: Expert opinion on biological therapy 20101101
Title: The therapy of kidney cancer with biomolecular drugs.
Journal: Cancer treatment reviews 20101101
Title: A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
Journal: Gynecologic oncology 20101001
Title: Pazopanib: in advanced renal cell carcinoma.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20101001
Title: Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Journal: The Lancet. Oncology 20101001
Title: Kinase inhibitors for refractory thyroid cancers.
Journal: The Lancet. Oncology 20101001
Title: Is advanced renal cell carcinoma becoming a chronic disease?
Journal: Lancet (London, England) 20100821
Title: Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping.
Journal: Journal of pharmaceutical and biomedical analysis 20100801
Title: Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
Journal: Neuro-oncology 20100801
Title: Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100801
Title: Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity.
Journal: Toxicologic pathology 20100801
Title: A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.
Journal: The oncologist 20100801
Title: Bar the windows but open the door to randomization.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100701
Title: Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100701
Title: Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100701
Title: Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib.
Journal: Journal of cellular biochemistry 20100701
Title: The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100701
Title: Targeted therapies: Pazopanib: carving a niche in a crowded therapeutic landscape.
Journal: Nature reviews. Clinical oncology 20100701
Title: Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.
Journal: The Annals of pharmacotherapy 20100601
Title: [Antiangionic drugs in soft tissue sarcoma].
Journal: Bulletin du cancer 20100601
Title: Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib.
Journal: Diabetes care 20100601
Title: (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.
Journal: The oncologist 20100601
Title: Effect of pazopanib on tumor microenvironment and liposome delivery.
Journal: Molecular cancer therapeutics 20100601
Title: Pazopanib trial data cannot support first-line use.
Journal: Nature reviews. Urology 20100601
Title: Everolimus and pazopanib: two new drugs for renal cell cancer.
Journal: The Medical letter on drugs and therapeutics 20100503
Title: Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.
Journal: Expert review of anticancer therapy 20100501
Title: Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.
Journal: British journal of cancer 20100427
Title: Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Journal: Molecular cancer therapeutics 20100401
Title: Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Journal: Molecular cancer therapeutics 20100401
Title: Pazopanib in renal cell carcinoma.
Journal: Clinical advances in hematology & oncology : H&O 20100401
Title: Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
Journal: Cancer research 20100315
Title: StatBite: FDA oncology drug product approvals in 2009.
Journal: Journal of the National Cancer Institute 20100224
Title: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100220
Title: Prognostic factors in patients treated with VEGF-targeted therapies.
Journal: Clinical advances in hematology & oncology : H&O 20100201
Title: Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100120
Title: Pazopanib.
Journal: Nature reviews. Drug discovery 20100101
Title: New weapons against kidney cancer. Two recent drug options appear to extend survival for kidney cancer patients who can't tolerate existing medications.
Journal: DukeMedicine healthnews 20100101
Title: New therapeutic strategies for renal cell carcinoma.
Journal: Urologic nursing 20100101
Title: Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines.
Journal: Oncogene 20091203
Title: Tyrosine kinase inhibitors and the thyroid.
Journal: Best practice & research. Clinical endocrinology & metabolism 20091201
Title: Pazopanib: therapeutic developments.
Journal: Expert opinion on pharmacotherapy 20091201
Title: Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
Journal: British journal of cancer 20091117
Title: Pazopanib: an antiangiogenic drug in perspective.
Journal: Future oncology (London, England) 20091101
Title: Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090910
Title: Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.
Journal: Journal of pharmaceutical and biomedical analysis 20090908
Title: Pazopanib for the treatment of renal cell carcinoma and other malignancies.
Journal: Drugs of today (Barcelona, Spain : 1998) 20090901
Title: Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor.
Journal: Oncology (Williston Park, N.Y.) 20090801
Title: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090701
Title: Phase I trial of pazopanib in patients with advanced cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090615
Title: Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Journal: Cancer 20090515
Title: Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).
Journal: Blood 20090507
Title: Targeted therapies in metastatic renal cancer in 2009.
Journal: BJU international 20090501
Title: Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib.
Journal: Archives of ophthalmology (Chicago, Ill. : 1960) 20090401
Title: Apical ballooning syndrome during treatment with a vascular endothelial growth factor receptor antagonist.
Journal: International journal of cardiology 20090124
Title: Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.
Journal: Current opinion in investigational drugs (London, England : 2000) 20081201
Title: Novel drugs for renal cell carcinoma.
Journal: Expert opinion on investigational drugs 20081001
Title: Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.
Journal: Journal of medicinal chemistry 20080814
Title: Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
Journal: Expert opinion on investigational drugs 20080201
Title: New drugs for ovarian cancer.
Journal: Clinical advances in hematology & oncology : H&O 20080201
Title: Signaling inhibitors in metastatic renal cell carcinoma.
Journal: Cancer journal (Sudbury, Mass.) 20080101
Title: American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 4.
Journal: IDrugs : the investigational drugs journal 20070801
Title: Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.
Journal: Molecular cancer therapeutics 20070701
Title: Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
Journal: Current oncology reports 20070301
Title: New treatment approaches in metastatic renal cell carcinoma.
Journal: Current opinion in urology 20060901
Title: Harris PA, et al. Discovery of 5-[-[(2,3-dimethyl-2H-indazol-6-yl)methylamino-2-pyrimidinylamino-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem. 2008, 51(15), 4632-4640.
Title: Thakur A, et al. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvasc Res. 2011 Nov;82(3):346-50.
